Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 25, 2019 16:01 ET | Source: MyoKardia, Inc.

MyoKardia Announces Proposed Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., March 25, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment...
March 06, 2019 08:00 ET | Source: MyoKardia, Inc.

MyoKardia to Present at Cowen & Co. 39th Annual Health Care Conference

SOUTH SAN FRANCISCO, Calif., March 06, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of serious...
March 04, 2019 08:02 ET | Source: MyoKardia, Inc.

MyoKardia Announces Positive Six-Month Safety and Efficacy Data from PIONEER-OLE Study of Mavacamten for the Treatment of Symptomatic, Obstructive HCM

Mavacamten Well Tolerated; Results Show Statistically Significant Elimination of Obstruction and Durable NYHA Class Improvements Statistically Significant Improvement in Several Key Biomarkers...
February 28, 2019 08:30 ET | Source: MyoKardia, Inc.

MyoKardia Reports Fourth Quarter and Full Year 2018 Financial Results

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment...
January 23, 2019 08:30 ET | Source: MyoKardia, Inc.

MyoKardia Appoints William Fairey as Chief Commercial Officer

SOUTH SAN FRANCISCO, Calif., Jan. 23, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment...
January 03, 2019 08:00 ET | Source: MyoKardia, Inc.

MyoKardia to Present at 37th Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan. 03, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of...
January 02, 2019 08:00 ET | Source: MyoKardia, Inc.

MyoKardia Regains Global Rights to Mavacamten and MYK-491 Programs from Sanofi

SOUTH SAN FRANCISCO, Calif., Jan. 02, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of...
December 11, 2018 08:30 ET | Source: MyoKardia, Inc.

MyoKardia Reports Positive Data from Phase 1b Single-Ascending Dose Clinical Trial of MYK-491 in Dilated Cardiomyopathy and Systolic Heart Failure Patients

MYK-491 Demonstrated Increase in Contractility Consistent with Data from Preclinical and Healthy Volunteer Studies Multiple-Ascending Dose Phase 2a Clinical Trial in DCM and Systolic Heart Failure...
December 05, 2018 16:01 ET | Source: MyoKardia, Inc.

MyoKardia to Present at the BMO 2018 Prescriptions for Success Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Dec. 05, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of...
November 12, 2018 07:30 ET | Source: MyoKardia, Inc.

MyoKardia Presents Preclinical Evidence of Mavacamten’s Novel Effect on Diastolic Compliance at the 2018 American Heart Association Scientific Sessions

Improved Left Ventricular Compliance Demonstrated in Genetic Pig Model of Non-Obstructed Hypertrophic Cardiomyopathy Results Add to Growing Body of Evidence of Mavacamten’s Dual Activity in...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right